Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Schizophrenia Drugs Market


4. Market Overview

4.1. Introduction

4.1.1. Schizophrenia Drugs Introduction

4.1.2. Market Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027

4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast


5. Key Insights

5.1. Pipeline Analysis: Schizophrenia Drugs

5.2. Value Chain Analysis

5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027


6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definitions

6.2. Key Findings / Developments

6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

6.3.1. First Generation Drugs

6.3.2. Second Generation Drugs

6.3.3. Third Generation Drugs

6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class


7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definitions

7.2. Key Findings / Developments

7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

7.3.1. Injectable

7.3.2. Oral

7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration


8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Schizophrenia Drugs Market Attractiveness, by Region


9. North America Schizophrenia Drugs Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

9.2.1. First Generation Drugs

9.2.2. Second Generation Drugs

9.2.3. Third Generation Drugs

9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

9.3.1. Injectable

9.3.2. Oral

9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Schizophrenia Drugs Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Route of Administration

9.5.3. By Country


10. Europe Schizophrenia Drugs Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

10.2.1. First Generation Drugs

10.2.2. Second Generation Drugs

10.2.3. Third Generation Drugs

10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

10.3.1. Injectable

10.3.2. Oral

10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Rest of Europe

10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis

10.5.1. By Drug Class

10.5.2. By Route of Administration

10.5.3. By Country/Sub-region


11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

11.2.1. First Generation Drugs

11.2.2. Second Generation Drugs

11.2.3. Third Generation Drugs

11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

11.3.1. Injectable

11.3.2. Oral

11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis

11.5.1. By Drug Class

11.5.2. By Route of Administration

11.5.3. By Country/Sub-region


12. Latin America Schizophrenia Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

12.2.1. First Generation Drugs

12.2.2. Second Generation Drugs

12.2.3. Third Generation Drugs

12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

12.3.1. Injectable

12.3.2. Oral

12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Route of Administration

12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

13.2.1. First Generation Drugs

13.2.2. Second Generation Drugs

13.2.3. Third Generation Drugs

13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

13.3.1. Injectable

13.3.2. Oral

13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis

13.5.1. By Drug Class

13.5.2. By Route of Administration

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)

14.2. Company Profiles

14.2.1. Allergan

14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.1.2. Financial Overview

14.2.1.3. Product Portfolio

14.2.1.4. SWOT Analysis

14.2.1.5. Strategic Overview

14.2.2. Otsuka Holdings Co., Ltd

14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.2.2. Financial Overview

14.2.2.3. Product Portfolio

14.2.2.4. SWOT Analysis

14.2.2.5. Strategic Overview

14.2.3. Janssen Pharmaceutica (Johnson & Johnson)

14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.3.2. Financial Overview

14.2.3.3. Product Portfolio

14.2.3.4. SWOT Analysis

14.2.3.5. Strategic Overview

14.2.4. Pfizer Inc.

14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.4.2. Financial Overview

14.2.4.3. Product Portfolio

14.2.4.4. SWOT Analysis

14.2.4.5. Strategic Overview

14.2.5. Maynepharma

14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.5.2. Financial Overview

14.2.5.3. Product Portfolio

14.2.5.4. SWOT Analysis

14.2.5.5. Strategic Overview

14.2.6. Vanda Pharmaceuticals Inc.

14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.6.2. Financial Overview

14.2.6.3. Product Portfolio

14.2.6.4. SWOT Analysis

14.2.6.5. Strategic Overview

14.2.7. Sumitomo Dainippon Pharma

14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.7.2. Financial Overview

14.2.7.3. Product Portfolio

14.2.7.4. SWOT Analysis

14.2.7.5. Strategic Overview

14.2.8. Eli Lilly & Co.

14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.8.2. Financial Overview

14.2.8.3. Product Portfolio

14.2.8.4. SWOT Analysis

14.2.8.5. Strategic Overview

14.2.9. AstraZeneca Plc

14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.9.2. Financial Overview

14.2.9.3. Product Portfolio

14.2.9.4. SWOT Analysis

14.2.9.5. Strategic Overview



List of Figures



Figure 01: Global Schizophrenia Drugs Market Analysis, by Route of Administration

Figure 02: Global Schizophrenia Drugs Market Analysis, by Drug Class

Figure 03: Global Schizophrenia Drugs Market Analysis, by Region

Figure 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 05: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018

Figure 06: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018

Figure 07: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018

Figure 08: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, 2017–2027

Figure 09: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 10: Global Schizophrenia Drugs Market Revenue (US$ Mn), by First Generation Drugs, 2017–2027

Figure 11: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Second Generation Drugs, 2017–2027

Figure 12: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Third Generation Drugs, 2017–2027

Figure 13: Global Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 14: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 15: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Oral Route of Administration, 2017–2027

Figure 16: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Injectable Route of Administration, 2017–2027

Figure 17: Global Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 18: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018 and 2027

Figure 19: Global Schizophrenia Drugs Market Attractiveness Analysis, by Region, 2019–2027

Figure 20: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 21: North America Schizophrenia Drugs Market Attractiveness Analysis, by Country, 2019–2027

Figure 22: North America Schizophrenia Drugs Market Value Share Analysis, by Country, 2018 and 2027

Figure 23: North America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 24: North America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 25: North America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 26: North America Schizophrenia drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 27: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 28: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 29: Europe Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 30: Europe Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 31: Europe Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 32: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 33: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 34: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 35: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 36: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 38: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 39: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 40: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 41: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 42: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 43: Latin America Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 44: Latin America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 45: Latin America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 46: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 47: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 48: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 49: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 50: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 51: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 52: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 53: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 54: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 55: Global Schizophrenia drugs Market Analysis, by Company Ranking, 2018

Figure 56: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 57: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 58: Johnson & Johnson Breakdown of Net Sales, by Region, 2018

Figure 59: Johnson & Johnson Breakdown of Net Sales, by Business Segment, 2018

Figure 60: Allergan Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 61: Allergan R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 62: Allergan Breakdown of Net Sales, by Business Segment (%), 2018

Figure 63: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016–2018

Figure 64: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 65: Otsuka Holdings Co. Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017

Figure 66: Otsuka Holdings Co. Ltd. R&D Spending and Sales & Distribution Spending (US$ Bn) – Company Level, 2016–2017

Figure 67: Otsuka Holdings Co. Ltd. Breakdown of Net Sales, by Region (Company Level), 2017

Figure 68: Otsuka Holdings Co. Ltd. Breakdown of Net Sales (Overall Company Level), 2017

Figure 69: Eli Lily and Company Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2016–2018

Figure 70: Eli Lily and Company Breakdown of Net Sales, by Neuroscience Level, 2018

Figure 71: Eli Lily and Company Breakdown of Net Sales, by Region, 2018

Figure 72: AstraZeneca Plc. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017

Figure 73: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018

Figure 74: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018 (%)

Figure 75: Mayne Pharma Group Limited Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016-2018

Figure 76: Mayne Pharma Group Limited Breakdown of Net Sales (%), by Region, 2018

Figure 77: Sumitomo Dainippon Pharma Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017

Figure 78: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Business Segment, 2017

Figure 79: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Region, 2017

Figure 80: Vanda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017


List of Tables


List of Tables

Table 01: Pipeline Analysis

Table 02: Depression Drugs Sales Analysis, 2015–2017

Table 03: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 05: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 09: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Schizophrenia drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 12: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 14: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 15: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 16: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 17: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 18: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 20: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027